Health
Novel Biologic Drug Shows Promise in Reducing COPD Exacerbations
AstraZeneca's tozorakimab significantly reduces COPD symptoms in smokers and ex-smokers, earning FDA priority review as the first biologic treatment for the condition.
Tag: tozorakimab
Business
AstraZeneca’s COPD Drug Shows Late-Stage Success, Fueling Blockbuster Sales Hopes
Full trial data for tozorakimab shows significant reduction in COPD flare-ups across diverse patient groups, boosting AstraZeneca's sales forecast above $5 billion.